Biopharma VC hit highest quarterly level since 2022, but challenges in exit landscape remain

0

23.08.2024 00:04

Fiercebiotech.com

Biopharma VC hit highest quarterly level since 2022, but challenges in exit landscape remain gmasson Thu, 08/22/2024 - 17:04